The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
over 60 just over a week ago.. so I expect this at least over 40-45... next week
absolute bargain at this price, with the vital first contract secured in the US plenty more will follow
seems like good price to get in...
Thanks for posting the q&a
Really Fascinating and ‘amazing’ work labskin are doing.
‘The Chinese regulator is looking to establish alternatives in vitro standards to animal testing. Labskin is in an excellent position to become a key part of the new regulatory environment emerging in the Chinese cosmetics market.’
Morning Paulcon, I have sent you a message on advfn (lse premium only) be good to compare notes.
Please ignore my last message
What does labskin have to do with skin ?
2/2
China still mandates that cosmetics safety has to be tested in animals although recent announcements have lifted restrictions on importing cosmetic products with alternative methods for safety assessment. The Chinese regulator is looking to establish alternatives in vitro standards to animal testing. Labskin is in an excellent position to become a key part of the new regulatory environment emerging in the Chinese cosmetics market.
In January 2020 Labskin signed a Memorandum of Understanding with the Innocare Group to promote innovation and cooperation on regulatory compliance without animal testing. To make our skin models more relevant to Asian markets, Labskin is collaborating with the University of Bradford to develop a model containing melanocytes so that next-generation skin models can be created using cells from donors with different ethnic backgrounds. Melanin is a natural sink of chemical compounds so different level of pigmentation could become an important factor not only for safety testing and efficacy.
Looking ahead 10 or 20 years from now, what does the future hold for the lab–grown human skin model? How far can you go?
At this point, there is no limit to what we can do with skin models. The most urgent matter to address is adding extra complexity. This includes the need for melanocytes and Langerhans cells, sourced to improve the immune response of the models. Research demonstrates that this is possible; it just needs to be commercially produced. The next step will be to add complex macrostructures, such as hair follicles, sweat and sebaceous glands, possibly by reprogramming stem cells. Blood vessels could be developed inside a 3D model like Labskin as we know that seeding endothelial cells into a skin model produces a self-organized microvasculature.
A combination of these techniques and 3D bioprinting will give rise to a new generation of skin models with blood/lymphatic vessels that could be connected to a microfluidic system, similar to our circulatory system, wired to keep the skin alive. All of this improvement combined with further developments in acute, chronic toxicology and efficacy will result in improved models.
https://connect.in-cosmetics.com/news-category/testing-regulations/a-reimagined-look-at-skin-model-testing-qa-with-labskin/
1SEPTEMBER 29, 2020
1/2
* An interview with David Caballero-Lima, R&D Manager, Labskin
Labskin has been around for twelve years – can you tell us about the history of the company as well as your field of expertise?
The Labskin model was created by a group of microbiologists at the University of Leeds to study the skin human microbiota and the microbial/host interaction in a controlled environment. Labskin has unique features, including its improved barrier function, dry surface and the expression of antimicrobial peptides which allow the colonization of the model with skin microbiome. We use these defining characteristics to develop methods for testing ingredients and formulations on the microbial community on Labskin.
We colonise Labskin with different microbial consortia containing mixes of skin bacteria and fungi. We can also isolate the whole microbiome from volunteers and transplant this microbiome onto Labskin. We can even challenge those consortia or microbiomes with pathogens. Then, combining a range of techniques such as colony counting, RT-qPCR, immunohistochemistry, ELISA or sequencing; we are able to look at the effect of those products on both the host and the microbiota at the same time.
We can’t avoid the obligatory question about Covid-19 and testing sanitizers… you collaborate with various universities and academics…any exciting initiatives you can share with us?
We regularly carry out tests on skin sanitisers, soaps and cleansers using our commensal skin consortia and specific pathogens. In the lab, our standard methods for testing sanitisers against the virus implement the most robust safety measures. We are now working with two leading universities with Containment Level 3 biosafety levels for specific laboratory work on SARS–CoV2.
Most data on the efficacy of hand sanitisers against the Covid-19 virus do not correlate to a real-life situation. We use our Labskin model to get data in an environment that closely resembles real human skin. Additionally, we isolate microbiome from volunteers and have developed methods to isolate those microbiomes without contact with the subject. In effect, we run remote clinical trials that use an internet portal to recruit and send swabs to the volunteers and recover the whole microbiomes from those volunteers to safely transplant them onto our skin models in our facilities.
Your 3-D skin model is a great alternative to animal testing in China. You are now also working on a melanocyte skin model for ethnic African and Asian skin… What can we look forward to internationally?
Great posts Paulcon62. I too expect a constant stream of positive news from our numerous revenue streams and believe Gerry has a few aces up his sleeve. You can tell he seems very confident with what he is building and the great progress made to date.
After a good RNS and positive market reaction is common with SKIN.
Expecting a further rise on the morrow.
Seems to agree.8 min 30 onwards
https://www.youtube.com/watch?v=WpMdqvTJLlM
Yes the podcast cuts out all the time for me too. I must have tried to watch it 10 times at least, and on different devices. Eventually I gave up. They need to fix that.
Paulcon, you gone all RNS on us ??
Happy from where Iam looking the sp finished up today. Really was great news this morning and Iam sure it is the start of many many more to come in the near term.It is obvious that waste water/sewage monitoring is going to be huge and as I have said before Skin +Mwg and soon to be Dvrg are in the perfect place with the right technology at the right time. Governments will be pushing this and maybe even throwing some money at it. Oh and we have numerous other revenue streams.
This is a crazy game. Company announces a £3 million contract and the SP goes down. However I still have faith. My experience is to never try and make any rhyme or reason of daily or weekly SP movements but the truth does eventually shinning through. Good news today with more highly likely to come in the near future. I'm chilled, SP will go up in time.
I appreciate that thinkaboutit.............!
so you a "NO" then .............:()
All the best (erm, I kinda thought that :()
and then somebody lets the next goon in. Thinkaboutit...another one in the iggy bin
Huge potential here.
Many countries are now starting to see the value in monitoring waste water!
www.news24.com/amp/news24/analysis/analysis-monitoring-our-wastewater-covid-19-is-in-our-poop
In July, we wrote and recommended that South Africa needed a Covid-19 wastewater and water quality surveillance programme. This was on the response by WRC and SALGA partnership May launch of the Water Quality (wastewater and non-sewer) National surveillance programme aimed to complement national initiatives in dealing with the pandemic.
Credit to you Chesh . A brave post.
In time AndyNich............... :)
we'll look at the yearly........... !
All the best (SP above 50,100,200 MA's an all................:()
Your offering up my confidence in my investment over Britishbulldogs thinkaboutit..................!
let me tell you straight,................. YES....... :()
All the best (DYOR..... IMO ....... an all that :)
Thinkaboutit,
What time frame are you using to recognise the downtrend? I hope its not daily?
On weekly chart it certainly looks like going down.
Its a different picture on monthly and 3 month chart.
People always complain about price manipulation.... it doesn't help you to think this way.
Every investor looking at a stock will perceive a different balance of risk to reward (that changes over time). This is visible in the lower and upper bounds in price oscillation over the current trend. The upper price bound representing buyers who perceive lower risker/higher reward, and the lower price bound representing buyers who perceive higher risk / lower reward. This means the current price is always somewhere in the range of the right price given current knowledge.
Knowing this was the case, regardless of your risk / reward view of the company, why would you every want to pay a price at the top of that range... the only time I do this is when I have no position at all but am very interested in a company. In doing so, I would never buy my whole position in one go, and then hope the price drops so I can add to m position at better value.
Hope that's useful to someone.
We both know this is on a downwards trend. Would you recommend a buy Chesh? I'm curious to see hoe credible your posts are. A yes or no will suffice.